Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin Lymphoma. PSMA ADC Produces Clinically Relevant Declines in PSA and CTC Counts. Enhancing ADCs to Target Diseased Cells and Deliver Payloads. Seattle Genetics and Bristol-Myers Squibb Evaluate New Combination of Brentuximab Vedotin and Nivolumab. and Bristol-Myers Squibb Company have entered into a clinical trial collaboration to evaluate the investigational c.

Auven Therapeutics is a private equity firm pursuing an innovative life science investment strategy. Although it utilizes a fund structure, it also has an internal drug development company that allows it to more effectively manage drug development and grow the value of its therapeutic assets. Sun Pharma Announces US FDA Acceptance of NDA for OTX-101. ADC Therapeutics is developing a pipeline of proprietary Antibody Drug Conju.

Since 1993, the firm has backed a series of ambitious entrepreneurs wanting to build outstanding businesses, three of which have been floated as public companies and eight of which have achieved other profitable exits. ET Capital Limited Cambridge UK Authorised and regulated by FCA.

This website uses cookies to collect statistical information on the use of our website with the goal of improving user experience. Read our cookie policy for more information. Click here to accept the use of cookies on our website. Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Full Year 2017 Financial Results. To listen to a replay of the webcast, here.

Ensuring that your audiences understand the essence of complex scientific and medical concepts is key to the communication of science. Clear visuals combined with well-focussed text are essential for optimal communication. Scicomvisuals brings expertise in both.